Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > RUSNANO Signs Investment Agreement for the SynBio Innovative Pharmaceuticals Project

Abstract:
RUSNANO, the Human Stem Cells Institute, Pharmsynthez, Cryonix, FDS Pharma LLP (United Kingdom), and private investor Dmitry Genkin have signed an investment agreement for the SynBio project. The project's purpose is to develop innovative medicines and biobetter pharmaceuticals. Lipoxen PLC, a British pharmaceuticals developer for leaders in the global pharmaceuticals industry, and German company SymbioTec GmbH will be the principal R&D partners for the project.

RUSNANO Signs Investment Agreement for the SynBio Innovative Pharmaceuticals Project

Moscow, Russia | Posted on August 5th, 2011

The partners have established limited liability company SynBio to carry out the project, which has a total budget of 3.2 billion rubles. Of that sum, RUSNANO will co-invest up to 1.3 billion rubles. The other founders will co-invest up to 1.9 billion rubles in the form of monetary resources, intellectual property rights, and shareholding in their own and subsidiary companies. The investment period will be four years, and the project is slated to run seven.

The SynBio project will develop and launch nine pharmaceutical products for Russian and international markets. The medicines are based on three technological platforms:

stem cell technologies for treatment of chronic diffuse liver disease (the Gemacell platform)
intranuclear human protein histone H1 for treatment of cancers and other diseases (the Histone platform)
sustained-release drugs using polysialic acid-biobetters for treatment of diabetes mellitus, Alzheimer's disease, chronic kidney disease, and other illnesses (the PolyXen® platform).

Biobetters resemble biotech pharmaceuticals that already exist in the market, and they differ in that they surpass the biotech preparations by certain characteristics, such as effectiveness.

All the medicines in the project are currently undergoing pre-clinical tests or clinical trials in research laboratories in Russia and Europe. All the pharmaceuticals developed within the project are expected to be sold in the Russian and international markets. Sales of SynBio's drugs in 2015 are forecasted at 700 million rubles.

"Two facilities will be established for commercial production of the innovative medicines, one each in Leningrad and Moscow oblasts," explained Olga Shpichko, RUSNANO managing director. "Manufacturing will be set up jointly with our German and British partners. We regard this as a step toward entering the international pharmaceuticals market."

Artur Isaev, general director of the Human Stem Cells Institute: "It would be difficult to over-estimate the importance of today's events for us and our partners. This is the first time that a Russian company has initiated a M&A in the biotechnology sector to serve the Russian and global markets. The project intends to introduce a number of innovative drugs that will bring real progress in the treatment of socially significant diseases. Our project is an excellent example of how the government's program for innovative development of the Russian pharmaceutical sector can be implemented."

####

About RUSNANO
RUSNANO was founded in March 2011 as an open joint stock company through reorganization of state corporation Russian Corporation of Nanotechnologies. RUSNANO’s mission is to develop the Russian nanotechnology industry through co-investment in nanotechnology projects with substantial economic potential or social benefit. The Government of the Russian Federation owns 100 percent of the shares in RUSNANO. Anatoly Chubais is CEO and chairman of the Executive Board of RUSNANO.

Work to establish nanotechnology infrastructure and training for nanotechnology specialists, formerly conducted by the Russian Corporation of Nanotechnologies, has been entrusted to the Fund for Infrastructure and Educational Programs, a non-commercial fund also established through reorganization of the Russian Corporation of Nanotechnologies.

OJSC HSCI (Human Stem Cells Institute, www.hsci.ruNew Window) is a Russian biotech company founded in 2003. The main focus of HSCI is scientific research and development as well as commercialization and marketing of innovative proprietary products and services arising from cell-based, gene and post-genome technologies. HSCI owns the largest personal storage repository of cord blood stem cells in Russia-Gemabank.

At present HSCI is in the process of registering the first gene-therapy drug in Russia, Neovasculgen (for treatment of ischemia of the lower limbs), is receiving approval for clinical trials of the first cell-based drug Gemacell (for treatment of ischemic heart disease and cirrhosis) and is beginning to market a comprehensive set of services for individual skin regeneration-SPRS therapy (based on a technology approved by the Russian health authorities for applying autologous dermal fibroblasts to correct the effects of aging and skin defects). The company is also in the final stages of readying for the launch a multifaceted project of HSCI and RUSNANO to develop and produce new unique medicines for the Russian and international markets (the SynBio project).
In December 2009 the Humans Stem Cells Institute made an initial public offering on MICEX (ticker symbol: ISKJ), becoming the first biotech company in Russia to go public. The beginning of trading of HSCI shares also marked the opening of the exchange’s Market for Innovations and Investments (MICEX MII), a platform for the innovation and growth companies sector created in cooperation with RUSNANО.

For more information, please click here

Contacts:
10A Prospekt 60-letia Oktyabrya
Moscow, Russia
117036
P: +7 495 988 5388
F: +7 495 988 5399

Copyright © RUSNANO

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Leti to Demo Wristband with Embedded Sensors to Diagnose Sleep Apnea: APNEAband, Which Will Be Demonstrated at CES 2018, Also Monitors Mountain Sickness, Dehydration, Dialysis Treatment Response and Epileptic Seizures December 12th, 2017

Leti Develops World’s First Micro-Coolers for CERN Particle Detectors: Leti Design, Fabrication and Packaging Expertise Extends to Very Large Scientific Instruments December 11th, 2017

Untangling DNA: Researchers filter the entropy out of nanopore measurements December 8th, 2017

Device makes power conversion more efficient: New design could dramatically cut energy waste in electric vehicles, data centers, and the power grid December 8th, 2017

VC/Funding/Angel financing/Loans/Leases/Crowdfunding

180 Degree Capital Corp. Leads Investment in TheStreet, Inc.; Investment Enables Removal of Capital Structure Overhang November 14th, 2017

180 Degree Capital Corp. Appoints Investment Banking Veteran Parker Weil to Its Board of Directors August 2nd, 2017

Forge Nano 2017: 1st Quarter Media Update April 20th, 2017

180 Degree Capital Corp. Announces the Start of Kevin Rendino as Chairman and Chief Executive Officer and Completion of its Transition to a Registered Closed-End Fund March 31st, 2017

Govt.-Legislation/Regulation/Funding/Policy

Wheat gets boost from purified nanotubes: Rice University toxicity study shows plant growth enhanced by -- but only by -- purified nanotubes December 6th, 2017

Arrowhead Presents New Clinical Data Demonstrating a Sustained Host Response in Hepatitis B Patients Following RNAi Therapy — Up to 5.0 log10 reduction in HBsAg observed; data presented at HEP DART 2017 — December 6th, 2017

Chinese market opens up for Carbodeon nanodiamonds: Carbodeon granted Chinese Patent for Nanodiamond-containing Thermoplastic Thermal Compounds December 4th, 2017

Researchers advance technique to detect ovarian cancer: Rice, MD Anderson use fluorescent carbon nanotube probes to achieve first in vivo success November 30th, 2017

Nanomedicine

Leti to Demo Wristband with Embedded Sensors to Diagnose Sleep Apnea: APNEAband, Which Will Be Demonstrated at CES 2018, Also Monitors Mountain Sickness, Dehydration, Dialysis Treatment Response and Epileptic Seizures December 12th, 2017

Untangling DNA: Researchers filter the entropy out of nanopore measurements December 8th, 2017

Arrowhead Presents New Clinical Data Demonstrating a Sustained Host Response in Hepatitis B Patients Following RNAi Therapy — Up to 5.0 log10 reduction in HBsAg observed; data presented at HEP DART 2017 — December 6th, 2017

Copper will replace toxic palladium and expensive platinum in the synthesis of medications: The effectiveness of copper nanoparticles as a catalyst has been proven December 5th, 2017

Announcements

Leti to Demo Wristband with Embedded Sensors to Diagnose Sleep Apnea: APNEAband, Which Will Be Demonstrated at CES 2018, Also Monitors Mountain Sickness, Dehydration, Dialysis Treatment Response and Epileptic Seizures December 12th, 2017

Leti Develops World’s First Micro-Coolers for CERN Particle Detectors: Leti Design, Fabrication and Packaging Expertise Extends to Very Large Scientific Instruments December 11th, 2017

Untangling DNA: Researchers filter the entropy out of nanopore measurements December 8th, 2017

Device makes power conversion more efficient: New design could dramatically cut energy waste in electric vehicles, data centers, and the power grid December 8th, 2017

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project